Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.14
NBS's Cash to Debt is ranked lower than
78% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. NBS: 1.14 )
Ranked among companies with meaningful Cash to Debt only.
NBS' s 10-Year Cash to Debt Range
Min: 0   Max: N/A
Current: 1.14

Equity to Asset 0.42
NBS's Equity to Asset is ranked lower than
76% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBS: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
NBS' s 10-Year Equity to Asset Range
Min: -40.98   Max: 0.92
Current: 0.42

-40.98
0.92
F-Score: 2
Z-Score: -4.04
M-Score: -2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -365.44
NBS's Operating margin (%) is ranked lower than
69% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. NBS: -365.44 )
Ranked among companies with meaningful Operating margin (%) only.
NBS' s 10-Year Operating margin (%) Range
Min: -10991.67   Max: -27.04
Current: -365.44

-10991.67
-27.04
Net-margin (%) -354.00
NBS's Net-margin (%) is ranked lower than
69% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NBS: -354.00 )
Ranked among companies with meaningful Net-margin (%) only.
NBS' s 10-Year Net-margin (%) Range
Min: -13154.35   Max: -33.38
Current: -354

-13154.35
-33.38
ROE (%) -97.51
NBS's ROE (%) is ranked lower than
81% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. NBS: -97.51 )
Ranked among companies with meaningful ROE (%) only.
NBS' s 10-Year ROE (%) Range
Min: -578.99   Max: -57.05
Current: -97.51

-578.99
-57.05
ROA (%) -50.63
NBS's ROA (%) is ranked lower than
70% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. NBS: -50.63 )
Ranked among companies with meaningful ROA (%) only.
NBS' s 10-Year ROA (%) Range
Min: -850.61   Max: -18.34
Current: -50.63

-850.61
-18.34
ROC (Joel Greenblatt) (%) -405.11
NBS's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NBS: -405.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80050   Max: -46.95
Current: -405.11

-80050
-46.95
Revenue Growth (3Y)(%) -21.30
NBS's Revenue Growth (3Y)(%) is ranked lower than
68% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. NBS: -21.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 196.7
Current: -21.3

0
196.7
EBITDA Growth (3Y)(%) -22.40
NBS's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. NBS: -22.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.8   Max: 14.3
Current: -22.4

-56.8
14.3
EPS Growth (3Y)(%) -24.50
NBS's EPS Growth (3Y)(%) is ranked lower than
71% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NBS: -24.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 9.6
Current: -24.5

-52.7
9.6
» NBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBS Guru Trades in

NBS Guru Trades in

Q3 2013

NBS Guru Trades in Q3 2013

Jim Simons 30,037 sh (New)
» More
Q4 2013

NBS Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
NBS's P/B is ranked higher than
87% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NBS: 1.70 )
Ranked among companies with meaningful P/B only.
NBS' s 10-Year P/B Range
Min: 0.59   Max: 150
Current: 1.7

0.59
150
P/S 4.24
NBS's P/S is ranked higher than
79% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. NBS: 4.24 )
Ranked among companies with meaningful P/S only.
NBS' s 10-Year P/S Range
Min: 0.72   Max: 360.71
Current: 4.24

0.72
360.71
Current Ratio 1.66
NBS's Current Ratio is ranked lower than
79% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NBS: 1.66 )
Ranked among companies with meaningful Current Ratio only.
NBS' s 10-Year Current Ratio Range
Min: 0.01   Max: 12.92
Current: 1.66

0.01
12.92
Quick Ratio 1.66
NBS's Quick Ratio is ranked lower than
74% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. NBS: 1.66 )
Ranked among companies with meaningful Quick Ratio only.
NBS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 12.92
Current: 1.66

0.01
12.92
Days Inventory 22.59
NBS's Days Inventory is ranked higher than
88% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. NBS: 22.59 )
Ranked among companies with meaningful Days Inventory only.
NBS' s 10-Year Days Inventory Range
Min: 15.69   Max: 457.38
Current: 22.59

15.69
457.38
Days Sales Outstanding 42.14
NBS's Days Sales Outstanding is ranked higher than
69% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. NBS: 42.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBS' s 10-Year Days Sales Outstanding Range
Min: 26.85   Max: 4506.17
Current: 42.14

26.85
4506.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
NBS's Dividend Yield is ranked lower than
88% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. NBS: 0.40 )
Ranked among companies with meaningful Dividend Yield only.
NBS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Dividend growth (3y) -100.00
NBS's Dividend growth (3y) is ranked lower than
80% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NBS: -100.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
NBS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -100
Current: -100

Yield on cost (5-Year) 0.40
NBS's Yield on cost (5-Year) is ranked lower than
92% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. NBS: 0.40 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NBS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Share Buyback Rate -54.60
NBS's Share Buyback Rate is ranked lower than
86% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NBS: -54.60 )
Ranked among companies with meaningful Share Buyback Rate only.
NBS' s 10-Year Share Buyback Rate Range
Min: -14.5   Max: -150.6
Current: -54.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
NBS's Price/Median PS Value is ranked higher than
92% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. NBS: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
NBS' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 3296.7
Current: 0.4

0.09
3296.7
Earnings Yield (Greenblatt) -77.10
NBS's Earnings Yield (Greenblatt) is ranked lower than
94% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NBS: -77.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -77.1   Max: 0
Current: -77.1

-77.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8NE1.Germany,
Neostem Inc was incorporated under the laws of the State of Delaware on September 18, 1980. It is engaged in cellular therapy industry. The Company develops novel proprietary cell therapy products. It is engaged in therapies that addresses ischemia through its CD34 Cell Program. AMR-001 is its product candidate in the CD34 Cell Program being developed to treat damaged heart muscle following an acute myocardial infarction. The Company competes with various companies like Lonza Group Ltd. and WuXi AppTec. The Company is subject to various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services.
» More Articles for NBS

Headlines

Articles On GuruFocus.com
Thursday’s Pre-Market Insights: GoPro Inc (GPRO), NeoStem Inc (NBS), Valeant Pharmaceuticals Intl May 28 2015 
"New To The Street"Announces Nationwide Broadcast Dec 03 2014 

More From Other Websites
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into... May 29 2015
8:27 am Neostem to change its corporate name to Caladrius Biosciences effective June 8, 2015 May 29 2015
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into... May 29 2015
NEOSTEM, INC. Files SEC form 8-K, Other Events May 29 2015
Neostem (NBS) Stock Declines After Pricing Secondary Public Offering May 28 2015
NeoStem Prices $25,000,000 Public Offering of Common Stock May 27 2015
NeoStem Prices $25,000,000 Public Offering of Common Stock May 27 2015
NeoStem Announces Proposed Public Offering of Common Stock May 27 2015
NeoStem Announces Proposed Public Offering of Common Stock May 27 2015
Betting On Cancer Treatment? Keep An Eye On This Company May 26 2015
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for... May 26 2015
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for... May 26 2015
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem May 21 2015
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem May 21 2015
10-Q for NeoStem, Inc. May 08 2015
NEOSTEM, INC. Files SEC form 10-Q, Quarterly Report May 06 2015
NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update May 05 2015
NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update May 05 2015
NeoStem to Present at Multiple May and June Conferences May 04 2015
NeoStem to Present at Multiple May and June Conferences May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK